LACTULOSE SOLUTION, USP

Manufacturer
Xttrium Laboratories, Inc.
Effective date
2026-04-14
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
7
Source
full-release
Hydrated at
2026-05-31 22:16:00

Label at a glance#

ProductLactulose
Active ingredientLACTULOSE
Label structure18 sections

Indications and uses

For the treatment of constipation. In patients with a history of chronic constipation, lactulose solution therapy increases the number of bowel movements per day and the number of days on which bowel movements occur.

Dosage and administration

The usual dose is 1 to 2 tablespoonfuls (15 to 30 mL, containing 10 g to 20 g of lactulose) daily. The dose may be increased to 60 mL daily if necessary. Twenty-four to 48 hours may be required to produce a normal bowel movement. NOTE: Some patients have found that lactulose solution may be more acceptable when mixed with fruit juice, water, or milk.

Label contents#

Full prescribing information#

LACTULOSE SOLUTION, USP

SPL UNCLASSIFIED SECTION

10g/15mL

For Oral Administration

Rx Only

DESCRIPTION

DESCRIPTION SECTION

​Lactulose solution is a synthetic disaccharide in solution form for oral administration. Each 15 mL of lactulose contains: 10 g lactulose (and less than 1.6 g galactose, less than 1.2 g lactose, and 1.2 g or less of other sugars). Also contains water, D&C Yellow No. 10, and FD&C Yellow No. 6. The pH range is 2.5 to 6.5.

Lactulose solution is a colonic acidifier which promotes laxation.

The chemical name for lactulose is 4-O-ß-D-galactopyranosyl-D-fructofuranose. It has the following structural formula:

structurestructure

C 12H 220 11

The molecular weight is 342.30. It is freely soluble in water.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Lactulose is poorly absorbed from the gastrointestinal tract and no enzyme capable of hydrolysis of this disaccharide is present in human gastrointestinal tissue. As a result, oral doses of lactulose reach the colon virtually unchanged. In the colon, lactulose is broken down primarily to lactic acid, and also to small amounts of formic and acetic acids, by the action of colonic bacteria, which results in an increase in osmotic pressure and slight acidification of the colonic contents. This in turn causes an increase in stool water content and softens the stool.

Since lactulose does not exert its effect until it reaches the colon, and since transit time through the colon may be slow, 24 to 48 hours may be required to produce the desired bowel movement.

Lactulose given orally to man and experimental animals resulted in only small amounts reaching the blood. Urinary excretion has been determined to be 3% or less and is essentially complete within 24 hours.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

For the treatment of constipation. In patients with a history of chronic constipation, lactulose solution therapy increases the number of bowel movements per day and the number of days on which bowel movements occur.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Since lactulose solution contains galactose (less than 1.6 g/15 mL), it is contraindicated in patients who require a low galactose diet.

WARNINGS

WARNINGS SECTION

A theoretical hazard may exist for patients being treated with lactulose solution who may be required to undergo electrocautery procedures during proctoscopy or colonoscopy. Accumulation of H2 gas in significant concentration in the presence of an electrical spark may result in an explosive reaction. Although this complication has not been reported with lactulose, patients on lactulose therapy undergoing such procedures should have a thorough bowel cleansing with a non-fermentable solution. Insufflation of CO 2 as an additional safeguard may be pursued but is considered to be a redundant measure.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Since lactulose solution contains galactose (less than 1.6 g/15 mL) and lactose (less than 1.2 g/15 mL), it should be used with caution in diabetics.

Information for Patients

INFORMATION FOR PATIENTS SECTION

In the event that an unusual diarrheal condition occurs, contact your physician.

Laboratory Tests

LABORATORY TESTS SECTION

Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically.

Drug Interactions

DRUG INTERACTIONS SECTION

Results of preliminary studies in humans and rats suggest that non-absorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH. Therefore, a possible lack of desired effect of treatment should be taken into consideration before such drugs are given concomitantly with lactulose solution.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

There are no known human data on long-term potential for carcinogenicity, mutagenicity, or impairment of fertility.

There are no known animal data on long-term potential for mutagenicity.

Administration of lactulose solution in the diet of mice for 18 months in concentrations of 3 and 10 percent (v/w) did not produce any evidence of carcinogenicity.

In studies in mice, rats, and rabbits, doses of lactulose solution up to 6 or 12 mL/kg/day produced no deleterious effects in breeding, conception, or parturition.

Pregnancy

PREGNANCY SECTION

Teratogenic Effects

Reproduction studies have been performed in mice, rats, and rabbits at doses up to 3 or 6 times the usual human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to lactulose. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when lactulose solution is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Precise frequency data are not available.

Initial dosing may produce flatulence and intestinal cramps, which are usually transient. Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia, and hypernatremia.

Nausea and vomiting have been reported.

To report SUSPECTED ADVERSE REACTIONS, contact Xttrium Laboratories, Inc. at 1-800-587-3721 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

OVERDOSAGE SECTION

Signs and Symptoms

There have been no reports of accidental overdosage. In the event of overdosage, it is expected that diarrhea and abdominal cramps would be the major symptoms. Medication should be terminated.

Oral LD50

The acute oral LD50 of the drug is 48.8 mL/kg in mice and greater than 30 mL/kg in rats.

Dialysis

Dialysis data are not available for lactulose. Its molecular similarity to sucrose, however, would suggest that it should be dialyzable.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The usual dose is 1 to 2 tablespoonfuls (15 to 30 mL, containing 10 g to 20 g of lactulose) daily. The dose may be increased to 60 mL daily if necessary. Twenty-four to 48 hours may be required to produce a normal bowel movement.

NOTE: Some patients have found that lactulose solution may be more acceptable when mixed with fruit juice, water, or milk.

HOW SUPPLIED

HOW SUPPLIED SECTION

Lactulose Solution, USP 10 g/15 mL is a colorless to yellow, unflavored solution available in the following container sizes:

15 mL unit dose white cups in trays of 10 cups (NDC 0116-4005-15)

30 mL unit dose white cups in trays of 10 cups (NDC 0116-4005-30)

8 fl. oz. (237 mL) white bottles (NDC 0116-4005-08)

16 fl. oz. (473 mL) white bottles (NDC 0116-4005-16)

32 fl. oz. (946 mL) white bottles (NDC 0116-4005-32)

Lactulose solution contains lactulose 667 mg/mL (10 g/15 mL).

Store at 20 ° to 25 °C (68 ° to 77 °F) [see USP Controlled Room Temperature]. Do not freeze.

Under recommended storage conditions, a normal darkening of color may occur. Such darkening is characteristic of sugar solutions and does not affect therapeutic action.

Prolonged exposure to temperatures above 30 °C (86 °F) or to direct light may cause extreme darkening and turbidity which may be pharmaceutically objectionable. If this condition develops, do not use.

Prolonged exposure to freezing temperatures may cause change to a semisolid, too viscous to pour. Viscosity will return to normal upon warming to room temperature.

Dispense in original container or in a tight, light-resistant container as defined in the USP, with a child-resistant closure.

To The Pharmacist: When ordering this product, include the product number (or NDC) in the description.

SPL UNCLASSIFIED SECTION

Rx Only

Revised: June 2024

Distributed by:

Xttrium Laboratories, Inc.

1200 E. Business Center Dr.

Mount Prospect, IL 60056

Prescribing Information Insert

SPL PATIENT PACKAGE INSERT SECTION

InsertInsert

InsertInsertInsertInsertInsertInsert

Lactulose 8-oz Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0116-4005-08

LACTULOSE SOLUTION, USP

10g/15mL

INDICATIONS: For the Treatment of Constipation

Each 15 mL of lactulose solution contains: 10 g lactulose (and less than 1.6 g galactose, less than 1.2 g lactose,
and 1.2 g or less of other sugars).


USUAL ADULT DOSAGE: 1 to 2 tablespoonfuls (15 to 30 mL) daily. See attached insert for full prescribing information.
Since lactulose does not exert its effect until it reaches the colon, and since transit time through the colon may be
slow, 24 to 48 hours may be required to produce a normal bowel movement.
Some patients have found that lactulose solution may be more acceptable when mixed with fruit juice, water, or milk.
Dispense in original container or in a tight, light-resistant container with child-resistant closure.
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Do not freeze.
Product may darken slightly but therapeutic action is not affected. Do not use if extreme darkening or turbidity occurs.
See accompanying product information.
Keep tightly closed.
PHARMACIST: When ordering this product, include the NDC number in the description.
Distributed by:
Xttrium Laboratories, Inc.
1200 E. Business Center Dr.
Mount Prospect, IL 60056

Rx Only

Net Contents: 8 fl oz (237mL)

4005LACT08LBLA

Rev. 06/2024

8oz bottle8oz bottle

8oz bottle8oz bottle

8oz bottle8oz bottle

Lactulose 16-oz Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0116-4005-16

LACTULOSE SOLUTION, USP

10g/15mL

INDICATIONS: For the Treatment of Constipation

Each 15 mL of lactulose solution contains: 10 g lactulose (and less than 1.6 g galactose, less than 1.2 g lactose,
and 1.2 g or less of other sugars).


USUAL ADULT DOSAGE: 1 to 2 tablespoonfuls (15 to 30 mL) daily. See attached insert for full prescribing information.
Since lactulose does not exert its effect until it reaches the colon, and since transit time through the colon may be
slow, 24 to 48 hours may be required to produce a normal bowel movement.
Some patients have found that lactulose solution may be more acceptable when mixed with fruit juice, water, or milk.
Dispense in original container or in a tight, light-resistant container with child-resistant closure.
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Do not freeze.
Product may darken slightly but therapeutic action is not affected. Do not use if extreme darkening or turbidity occurs.
See accompanying product information.
Keep tightly closed.

PHARMACIST: When ordering this product, include the NDC number in the description.


Distributed by:
Xttrium Laboratories, Inc.
1200 E. Business Center Dr.
Mount Prospect, IL 60056

Rx Only

Net Contents: 16 fl oz (473mL)

4005LACT16LBLA

Rev. 06/2024

16oz bottle16oz bottle

16oz bottle16oz bottle

16oz bottle16oz bottle

Lactulose 32-oz Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0116-4005-32

LACTULOSE SOLUTION, USP

10g/15mL

INDICATIONS: For the Treatment of Constipation

Each 15 mL of lactulose solution contains: 10 g lactulose (and less than 1.6 g galactose, less than 1.2 g lactose,
and 1.2 g or less of other sugars).

USUAL ADULT DOSAGE: 1 to 2 tablespoonfuls (15 to 30 mL) daily. See attached insert for full prescribing information.
Since lactulose does not exert its effect until it reaches the colon, and since transit time through the colon may be
slow, 24 to 48 hours may be required to produce a normal bowel movement.
Some patients have found that lactulose solution may be more acceptable when mixed with fruit juice, water, or milk.
Dispense in original container or in a tight, light-resistant container with child-resistant closure.
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Do not freeze.
Product may darken slightly but therapeutic action is not affected. Do not use if extreme darkening or turbidity occurs.
See accompanying product information.
Keep tightly closed.


PHARMACIST: When ordering this product, include the NDC number in the description.


Distributed by:
Xttrium Laboratories, Inc.
1200 E. Business Center Dr.
Mount Prospect, IL 60056

Rx Only

Net Contents: 32 fl oz (946 mL)

4005LACT32LBLA

Rev. 06/2024

32 oz bottle32 oz bottle

32 oz bottle32 oz bottle

32 oz bottle32 oz bottle

LACTULOSE 15mL UNIT DOSE CUP

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

UNIT DOSE

Delivers 15mL

NDC 0116-4005-15

LACTULOSE SOLUTION, USP

10g/15mL

Rx Only

Xttrium Laboratories, Inc.

Mount Prospect, IL 60056

4005LACT15LIDA

15 ml lid15 ml lid

LACTULOSE 30 mL UNIT DOSE CUP

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

UNIT DOSE

Delivers 30mL

NDC 0116-4005-30

LACTULOSE SOLUTION, USP

20g/30mL

Rx Only

Xttrium Laboratories, Inc.

4005LACT30LIDA

30 ml lid30 ml lid

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
391937lactulose 10 GM in 15 mL Oral SolutionPSN7
391937lactulose 667 MG/ML Oral SolutionSCD7
391937lactulose 10 GM per 15 ML Oral SolutionSY7
391937lactulose 20 GM per 30 ML Oral SolutionSY7

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
LACTULOSE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
Data codeCode 128301164005154lactulose lid 15ml.jpg
Data codeCode 128301164005307lactulose lid 30 ml.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
13620a32-e3b4-4aad-8280-283dce30ddffProduct name120260105
27883b46-af31-44b0-b4ce-e6b4f6d825a7Product name420250812
c1a80c95-0e51-52a0-75fa-75808f51ded8Product name220150421

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0116-4005-08Lactulose237 mL in 1 BOTTLESOLUTION2377
0116-4005-10Lactulose100 in 1 CASESOLUTION1007
0116-4005-11Lactulose100 in 1 CASESOLUTION1007
0116-4005-15Lactulose15 mL in 1 CUP, UNIT-DOSESOLUTION157
0116-4005-16Lactulose473 mL in 1 BOTTLESOLUTION4737
0116-4005-30Lactulose30 mL in 1 CUP, UNIT-DOSESOLUTION307
0116-4005-32Lactulose946 mL in 1 BOTTLESOLUTION9467
0116-4005-40Lactulose10 in 1 TRAYSOLUTION107
0116-4005-40Lactulose40 in 1 CASESOLUTION407
0116-4005-41Lactulose40 in 1 CASESOLUTION407
0116-4005-41Lactulose10 in 1 TRAYSOLUTION107

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0116-4005-08ML - Milliliter0116-4005f7ea2d68-651b-40ae-b2f8-a3eb54ef076f12023-10-16
0116-4005-11ML - Milliliter0116-40056ba03cdd-584d-42d1-9502-0a036d3803df12024-02-14
0116-4005-15ML - Milliliter0116-400511777ba0-6857-4c8d-8508-c3829847a24e12024-02-14
0116-4005-16ML - Milliliter0116-40053451d8c5-188f-4933-aba3-ae2f8e0fdbe512023-04-07
0116-4005-30ML - Milliliter0116-4005f1c0f6c8-48e0-41a6-b878-6217959a472112024-02-14
0116-4005-32ML - Milliliter0116-400523ad189f-3f05-4fb3-b711-3cb594e8928012024-02-14
0116-4005-40ML - Milliliter0116-400569479b61-fb23-48cd-b159-002da8f34bb212024-02-14
0116-4005-41ML - Milliliter0116-40056725bfb2-3713-441f-96d1-afc7805d526312024-02-14

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 4 matching rows.

NDC Codes#

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 4 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A075911-001LACTULOSELACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-21

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A075911-001AA

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-2184e616aacf4f…
2026-08-18 06:07:402026-07A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-21caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-21011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-2131067a03dcf5…
2025-08-23 18:47 UTC2025-08A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-216a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-21fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-21b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-2103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-212680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-215bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-21d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-21d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-2179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-21301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-211e350fbaab3a…
2024-05-31 18:47 UTC2024-05A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-218072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-215c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-215d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-214b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-2174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-21bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-21782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-2187673890dc5c…
2021-03-12 10:30 UTC2021-03A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-215aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-218869cabd3fbd…
2020-11-12 02:37 UTC2020-11A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-21c0c555d07b60…
2019-12-14 00:12 UTC2019-12A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-213f01610625f2…
2019-09-15 20:21 UTC2019-09A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-21b00525d2431f…
2019-07-19 19:46 UTC2019-07A075911-001LACTULOSE10GM/15MLSOLUTION / ORAL2002-02-21ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-216a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-211c564ffb4f44…
2023-12-20 04:57 UTC2023-12A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-21ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-21a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-219b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-21a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-213f0d92c62455…
2023-05-13 08:27 UTC2023-05A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-21053a50430f4f…
2023-01-26 05:58 UTC2023-01A075911-001LACTULOSE10GM/15MLSOLUTION / ORAL2002-02-213bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-213a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A075911-001LACTULOSE10GM/15MLSOLUTION / ORALAA2002-02-21f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 41 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A075911-001AA184e616aacf4f…
2026-08-18 06:07:402026-07A075911-001AA1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A075911-001AA1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A075911-001AA131067a03dcf5…
2025-08-23 18:47 UTC2025-08A075911-001AA16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A075911-001AA1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A075911-001AA1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A075911-001AA103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A075911-001AA12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A075911-001AA15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A075911-001AA1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A075911-001AA1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A075911-001AA179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A075911-001AA1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A075911-001AA11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A075911-001AA18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A075911-001AA15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A075911-001AA15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A075911-001AA14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A075911-001AA174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A075911-001AA1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A075911-001AA1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A075911-001AA187673890dc5c…
2021-03-12 10:30 UTC2021-03A075911-001AA15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A075911-001AA18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A075911-001AA1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A075911-001AA13f01610625f2…
2019-09-15 20:21 UTC2019-09A075911-001AA1b00525d2431f…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A075911-001AA16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A075911-001AA11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A075911-001AA1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A075911-001AA1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A075911-001AA19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A075911-001AA1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A075911-001AA13f0d92c62455…
2023-05-13 08:27 UTC2023-05A075911-001AA1053a50430f4f…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A075911-001AA13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A075911-001AA1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A075911-001AA1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A075911-001AA1cb3db0bc1861…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
LactuloseLACTULOSEXttrium Laboratories, Inc.df62ad54-5aba-4d05-e053-2a95a90aa48d2026-04-14Warnings, Adverse reactionsExact identifier
ndc (package): 0116-4005-32
ndc (package): 0116-4005-08
ndc (package): 0116-4005-30
ndc (package): 0116-4005-41
ndc (package): 0116-4005-11
ndc (package): 0116-4005-15
ndc (package): 0116-4005-10
ndc (package): 0116-4005-16
ndc (package): 0116-4005-40
ndc (product): 0116-4005
ndc11 (package): 00116400511
ndc11 (package): 00116400530
ndc11 (package): 00116400532
ndc11 (package): 00116400516
ndc11 (package): 00116400508
ndc11 (package): 00116400510
ndc11 (package): 00116400515
ndc11 (package): 00116400541
ndc11 (package): 00116400540
spl id: 4f6f0368-4b59-a9df-e063-6294a90ae43c
spl set id: df62ad54-5aba-4d05-e053-2a95a90aa48d

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.